GOINPHARMA: 24/7 Breaking News about pharma, healtcare, chemistry
Sunday, 19 May 2019 - 13:20

Top stories

News of the week

Money, money, money! Allergan, Pfizer, Amgen show that pharma sector still has the best numbers–EBITDA >40%

Three of the largest pharmaceutical groups in the world–Pfizer, Amgen and Allergan–have announced their FY2018 financial results over the last two days. It is clear that the pharma sector is still one of the industries ensuring the best financial return…

Good latest quarter from BMS

Approvals

Procedures / New drug and device authorizations / Recommendations

Positive momentum for Amgen: FDA recommends Evenity (osteoporosis)

An advisory panel at FDA has voted to recommend Evenity, an osteoporosis treatment co-developed with Belgium-based UCB. The positive opinion reflects a successful Phase III clinical trial conducted by Amgen to assess the product on a sample of patients with…

Companies

Healthcare market news

Money, money, money! Allergan, Pfizer, Amgen show that pharma sector still has the best numbers–EBITDA >40%

Three of the largest pharmaceutical groups in the world–Pfizer, Amgen and Allergan–have announced their FY2018 financial results over the last two days. It is clear that the pharma sector is still one of the industries ensuring the best financial return…

Chemistry

Market and Technology

Steilemann explains reasons for Covestro’s hard momentum

The Rheinische Post has published today a long interview to Markus Steilemann, head of German chemical group Covestro. Covestro last November announced a profit warning and its shares declined from €95 to €43 over few months (Frankfurt). This difficult momentum,…

M&A

Mergers & Acquisitions

Zambon targets €100m acquisition in China and US

The CEO of Italy-based Zambon, Roberto Tascione, former head of BMS Italy, has reportedly said in an interview to Reuters that his group is seeking acquisitions in China and the US. The sectors targeted by the company are respiratory and…

Nutraceuticals

Food supplements

Vitamin D myth starts shaking

The New York Times has published today a long article about the controversial views on vitamin D in the scientific community and its economic implications. One of the most fervent supporters of vitamin D, convinced that it brings high benefit…

Pathology

Latest developments

Robust Phase III data from Keytruda in patients with esophagus cancer

US-based Merck & Co. yesterday announced clinical results from its Phase-III KEYNOTE-181 clinical trial conducted on patients with metastatic esophageal cancer treated with the anti-PD-1 immunotherapy Keytruda. The results are highly positive and show a significant increase in overall survival…

Safety

News on Product Safety

FDA issues warning about Intercept’s Ocaliva after 19 patients died

The FDA has officially warned doctors about the risks from Intercept Pharmaceuticals’ Ocaliva (obeticholic acid), after 19 patients on Intercept’s drug, developed to treat PBC (Primary Biliary Cholangitis) had died. The FDA, anyway, has specified that the deaths have occurred…

Trials

Preclinical Trials / Clinical Trials / Epidemiology

Robust Phase III data from Keytruda in patients with esophagus cancer

US-based Merck & Co. yesterday announced clinical results from its Phase-III KEYNOTE-181 clinical trial conducted on patients with metastatic esophageal cancer treated with the anti-PD-1 immunotherapy Keytruda. The results are highly positive and show a significant increase in overall survival…